| Assessment of HPHC Exposure in Smokers Switching to THS/TP18 With Different Device Variants (NCT07443631) | Philip Morris Products S.A. | 2026-02-19 |
| Pharmacokinetics and Pharmacodynamics of THS With LEVIA Compared to THS With TEREA and to Cigarettes (NCT07459712) | Philip Morris Products S.A. | 2026-02-01 |
| Exploratory Randomized, Controlled, Dose-response Study on the Impact of Nicotine From Five Variants of a Nicotine Tablet (NICOTINE TABLET) on Attention (NCT07408180) | Philip Morris Products S.A. | 2025-10-28 |
| Nicotine Pharmacokinetics and Pharmacodynamics of Two Variants of VM 1.0 Compared to Cigarettes in Adult Current Smokers (NCT07135648) | Philip Morris Products S.A. | 2025-07-17 |
| Symptoms and Functions in Patients With COPD and Chronic Bronchitis Switching From CIG to THS (NCT07108166) | Philip Morris Products S.A. | 2025-04-02 |
| Pharmacokinetics and Comparative Bioavailability of Nicotine From Two Variants of NP2, NP2-4mg and NP2-6mg, Compared to Nicotine Lozenge 4mg (Loz-4mg) and Nicotine Gum 4mg (Gum-4mg) (NCT06171490) | Philip Morris Products S.A. | 2023-10-20 |
| Effect of Switching From Cigarette Smoking to THS on Systemic Endothelial Function in Subjects With Established Atherosclerotic Disease (NCT05566678) | Philip Morris Products S.A. | 2023-03-15 |
| Nicotine Pharmacokinetics of THS Single Use of a Regular or a Menthol Stick Compared to CIG (NCT05789420) | Philip Morris Products S.A. | 2023-02-16 |
| Effect of Switching From Cigarette Smoking to THS on Disease Progression in Mild to Moderate COPD Subjects With Chronic Bronchitis Symptoms. (NCT05569005) | Philip Morris Products S.A. | 2022-12-16 |
| Reduced Exposure to HPHC in Smokers Switching From Cigarettes to Different Versions of THS (NCT05599451) | Philip Morris Products S.A. | 2022-11-04 |
| Reduced HPHC Exposure in Cigarette Smokers Switching to P4M3 Gen. 2.0 Compared to Continuing Smoking, or Smoking Abstinence (NCT05487456) | Philip Morris Products S.A. | 2022-07-15 |
| Reduction of Exposure, Inflammation, and Oxidative Stress Following at Least 2 Years of Switching to THS Use Compared to Cigarette Smoking (NCT05385055) | Philip Morris Products S.A. | 2022-06-13 |
| Nicotine Pharmacokinetics Following Use of the P4M3 Gen 2.0 E-Cigarette Compared to Smoking Cigarettes (NCT05383508) | Philip Morris Products S.A. | 2022-04-28 |
| Nicotine Pharmacokinetics and Subjective Effects of Nicotine Pouch 1.0 Compared to Velo® Ice Cool and Zyn® Cool Mint Mini Dry in Healthy Smokers (NCT05317195) | Philip Morris Products S.A. | 2022-03-15 |
| Product Use and Adaptation, Safety and Tolerability of P3P in Adult Healthy Smokers Switching to it (NCT03953183) | Philip Morris Products S.A. | 2019-04-23 |
| Effect of Switching From Cigarette Smoking to IQOS on Exercise Capacity (NCT03887117) | Philip Morris Products S.A. | 2019-02-01 |
| Comparison of Abdominal Aortic Aneurysm Growth in Adult Smoking Patients Who Either Switch to IQOS, Continue Smoking, or Quit Smoking. (NCT03837704) | Philip Morris Products S.A. | 2018-10-03 |
| Cross-Sectional Survey on the Use of Tobacco Products - Italy (NCT03527004) | Philip Morris Products S.A. | 2018-03-20 |
| Cross-Sectional Survey on the Use of Tobacco Products - Germany (NCT03527017) | Philip Morris Products S.A. | 2018-03-12 |
| Cross-Sectional Survey on the Use of Tobacco Products - London (UK) (NCT03527030) | Philip Morris Products S.A. | 2018-03-08 |
| Real-Life Passive Exposure Assessment of IQOS (NCT03550989) | Philip Morris Products S.A. | 2017-12-05 |
| Effect of Switching From Cigarette Smoking to the Use of IQOS on Periodontitis Treatment Outcome (NCT03364751) | Philip Morris Products S.A. | 2017-11-07 |
| Nicotine Pharmacokinetics and Pharmacodynamics, Safety and Tolerability of P3P (NCT03369340) | Philip Morris Products S.A. | 2017-11-07 |